- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Illumina Inc(ILMN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ILMN
11/13/2026: ILMN (5-star) is currently NOT-A-BUY. Pass it for now.
Illumina Inc is a leading life sciences tools company specializing in next-generation DNA sequencing systems and consumables. The company benefits from an entrenched global installed base, high-margin recurring consumable revenue, and strong operating profitability. Its primary investment growth driver is the expansion of clinical oncology testing and population-scale genomics, supported by flagship platforms like the NovaSeq X. However, the company faces key risks including biopharma budget cyclicality, growing competition in long-read sequencing, and valuation sensitivity. Illumina suits growth-oriented healthcare investors willing to monitor research spending trends and clinical adoption milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While operating in secularly growing genomics markets, Illumina's near-term top-line growth has slowed to low-single digits. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal depends on favorable technical breakouts and positive sentiment shifts following margin improvements and clinical adoption updates. |
| Value investor | Mixed fit | Valuation multiples remain elevated relative to slow near-term organic revenue growth rates. |
| Dividend investor | Weak fit | Illumina does not pay a dividend, focusing entirely on reinvestment and capital allocation. |
| Low-risk investor | Weak fit | The stock exhibits moderate-to-high volatility driven by biopharma funding cycles and regulatory overhangs. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock frequently reacts sharply to quarterly consumable order fluctuations and biopharma spending trends. |
| Valuation risk | Medium / high | Forward P/E multiples leave little room for error if macro pressures weigh on instrument demand. |
| Competition risk (alternative sequencing and long-read technologies) | Medium | Emerging competitors trying to capture niche segments in long-read or single-cell sequencing pose a long-term threat. |
| Business quality | Strong | Illumina possesses a robust franchise moat anchored by an entrenched installed base and high consumable lock-in. |
| Dividend income | Low / none | Income-focused investors receive no cash return from dividends. |
| Execution risk | Medium | Management must successfully execute post-restructuring goals and integrate new proteomics additions like SomaLogic. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 31.30B USD | Price to earnings Ratio 35.63 | 1Y Target Price 261.45 |
Price to earnings Ratio 35.63 | 1Y Target Price 261.45 | ||
Volume (30-day avg) 2.4M shares | Beta 1.45 | 52 Weeks Range 112.65 - 309.35 | Updated Date 11/15/2026 |
52 Weeks Range 112.65 - 309.35 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.81 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 132.98% | Avg. Invested days 64 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Consumables | Reagents, flow cells, and sample preparation kits required to run genetic analyzers on an ongoing basis. | This is the core profit engine, acting like a razor-and-blade model with steady repeat customer orders. |
| Instruments | Sales and leasing of high-throughput and benchtop sequencers such as the NovaSeq and NextSeq lines. | Instrument sales establish the installed base that subsequently locks customers into buying high-margin consumables. |
| Services and Informatics | Instrument service contracts, customer support, and cloud-based software analytics platforms like DRAGEN. | Provides stable, recurring support revenue and enhances workflow stickiness for laboratories. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 1.36 | Actual 1.44 |
Profitability
Profit Margin 19.72% | Operating Margin (TTM) 19.06% |
Management Effectiveness
Return on Assets (TTM) 8.32% | Return on Equity (TTM) 32.39% |
Valuation
Trailing PE 35.63 | Forward PE 33.56 | Enterprise Value 32.28B | Price to Sales(TTM) 6.9 |
Enterprise Value 32.28B | Price to Sales(TTM) 6.9 | ||
Enterprise Value to Revenue 7.11 | Enterprise Value to EBITDA 22.54 | Shares Outstanding 151.20M | Shares Floating 150.69M |
Shares Outstanding 151.20M | Shares Floating 150.69M | ||
Percent Insiders 0.94 | Percent Institutions 113.5 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

